Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Diagnosis Of Multidrug-resistant Tuberculosis And Extensively Drug-resistant Tuberculosis: Current Standards And Challenges.

G. Migliori, A. Matteelli, D. Cirillo, M. Pai
Published 2008 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
INTRODUCTION The emergence of multidrug-resistant tuberculosis (MDR-TB) and, more recently, extensively drug-resistant TB (XDR-TB) is widely considered a serious threat to global TB control. Over 400,000 new cases of MDR-TB occur each year and, although their rates are currently unknown, XDR-TB cases have been detected in every country where there is capacity to detect them (including Canada). METHODS The present article provides a narrative overview of the various diagnostic options available for XDR-TB, including conventional tools and newer rapid tests for drug resistance. Available data suggest that automated liquid cultures are highly accurate and their use is rapidly expanding. Newly developed phenotypic tests include TK Medium (Salubris Inc, USA), microscopic-observation drug-susceptibility assay, FASTPlaque-Response bacteriophage assay (Biotec Laboratories Ltd, UK), colorimetric redox indicator methods and the microcolony method. These tests are usually cheaper but not always simple to perform, with some requiring high standards of biosafety and quality control. Among the newly developed phenotypic methods, reverse hybridization-based assays, referred to as line probe assays, represent a useful tool because of their superior accuracy and cost-effectiveness. CONCLUSIONS To effectively address the threats of MDR-TB and XDR-TB, global initiatives are required to scale-up culture and drug susceptibility testing capacities, especially in high-burden countries where such capacity is scarce. In parallel, efforts are needed to expand the use of novel and emerging technologies (ie, molecular diagnostics) for the rapid determination of drug resistance.
This paper references
Microscopic observation drug susceptibility assay for the diagnosis of TB
T. Munir (2007)
10.1586/14737159.6.3.423
New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance
M. Pai (2006)
10.1016/S0140-6736(06)68386-4
Progress towards improved tuberculosis diagnostics for developing countries
M. Perkins (2006)
Application of the Genotype MTBDR assay directly on sputum specimens.
D. Hillemann (2006)
Clinical and operational value of the XDR - TB definition
PC Hopewell (2007)
10.1186/1471-2334-5-62
A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis
M. Morgan (2005)
10.1093/JAC/DKL477
Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
A. Martin (2007)
10.1586/14787210.5.5.857
Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control
A. Matteelli (2007)
10.1016/S1473-3099(06)70628-4
International standards for tuberculosis care.
P. Hopewell (2006)
Evaluation of a rapid culture method for tuberculosis diagnosis: a Latin American multi-center study.
J. Robledo (2006)
10.1183/09031936.00001307
125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is “science” enough to tackle the epidemic?
G. Migliori (2007)
10.1086/518656
Facing the crisis: improving the diagnosis of tuberculosis in the HIV era.
M. Perkins (2007)
10.1016/J.JINF.2005.05.017
Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis.
M. Pai (2005)
The use of liquid medium for culture and DST
JA Robledo
New tools and emerging technologies for the diagnosis of tuberculosis: Part 1. Latent tuberculosis
M Pai (2006)
10.3201/eid1303.061400
Worldwide Emergence of Extensively Drug-resistant Tuberculosis
N. S. Shah (2007)
10.1086/505877
Global incidence of multidrug-resistant tuberculosis.
M. Zignol (2006)
10.1128/JCM.44.3.688-692.2006
Multicenter Laboratory Validation of the BACTEC MGIT 960 Technique for Testing Susceptibilities of Mycobacterium tuberculosis to Classical Second-Line Drugs and Newer Antimicrobials
S. Rüsch-Gerdes (2006)
SMIRA/TBNET Study Group. Clinical and operational value of the XDR-TB definition
GB Migliori (2007)
10.1128/JCM.00521-07
Evaluation of the GenoType MTBDRplus Assay for Rifampin and Isoniazid Susceptibility Testing of Mycobacterium tuberculosis Strains and Clinical Specimens
D. Hillemann (2007)
10.4103/0255-0857.32711
Introducing MODS: a low-cost, low-tech tool for high-performance detection of tuberculosis and multidrug resistant tuberculosis.
L. Caviedes (2007)



This paper is referenced by
10.1371/journal.pone.0018632
Experimental Tuberculosis in the Wistar Rat: A Model for Protective Immunity and Control of Infection
A. Singhal (2011)
10.1007/978-3-319-97373-9_6
New Governance Models for Discoveries of Vaccine Science
Ellie Okada (2019)
Oral medicine case book 68 : Oral ulceration caused by rifampicin-resistant tuberculosis ACRONYMS
(2015)
10.1128/JCM.00201-10
Evaluation of the MTBDRsl Test for Detection of Second-Line-Drug Resistance in Mycobacterium tuberculosis
V. S. Kiet (2010)
10.3201/eid/1706.101471
Multiple introductions of multidrug-resistant tuberculosis into households, Lima, Peru.
T. Cohen (2011)
10.1007/978-3-642-15742-4_30
Pulmonary Mycobacterial Infections in Patients with Hematological Malignancies
K. Al-Anazi (2011)
INVESTIGATION OF ANTIMYCOBACTERIAL AND CYTOTOXICITY ACTIVITY OF BERSAMA ABYSSINICA FRESEN EXTRACTS FROM TANZANIA
M. Chacha (2014)
10.1128/JCM.01111-17
Genetic Mimetics of Mycobacterium tuberculosis and Methicillin-Resistant Staphylococcus aureus as Verification Standards for Molecular Diagnostics
E. Machowski (2017)
10.15446/RSAP.V16N1.31316
Agar de capa delgada: Una opción costo-efectiva para el diagnóstico rápido de tuberculosis multirresistente
José M. Hernández-Sarmiento (2014)
10.4314/THRB.V18I2.5
The role of nontuberculous mycobacteria in the diagnosis, management and quantifying risks of tuberculosis in Tanga, Tanzania
A. S. Hoza (2016)
10.1128/JCM.00128-10
Evaluation of the Analytical Performance of the Xpert MTB/RIF Assay
Robert Blakemore (2010)
10.1016/j.ijmyco.2016.01.003
Use of RODAC plates to measure containment of Mycobacterium tuberculosis in a Class IIB biosafety cabinet during routine operations
G. Daneau (2016)
10.1016/j.ijtb.2017.03.006
Extensively Drug-resistant Tuberculosis (XDR-TB): A daunting challenge to the current End TB Strategy and policy recommendations.
M. A. Rahman (2017)
10.1177/2049936115624630
The implications of whole-genome sequencing in the control of tuberculosis
Robyn S Lee (2016)
Drug Resistance Mechanisms and Molecular Diagnosis Methods forTuberculosis
Tekeba Sisay (2019)
10.5897/AJMR11.358
Rapid detection of rpoB and katG genes from the sputum of multidrug-resistant Mycobacterium tuberculosis by polymerase chain reaction (PCR)-direct sequencing analysis
Song Yang (2011)
10.1128/9781555816728.CH73
Susceptibility Test Methods: Mycobacteria, Nocardia, and Other Actinomycetes*
G. Woods (2011)
10.1080/14656566.2017.1365837
Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India
M. Muniyandi (2017)
The role of the TB T-spot test in patients with tubercular retinal vasculitis
E. Lee (2016)
10.1155/2018/5456074
Sentinel Amenable Mortality: A New Way to Assess the Quality of Healthcare by Examining Causes of Premature Death for Which Highly Efficacious Medical Interventions Are Available
Montse Vergara-Duarte (2018)
Patrones tomográficos en tuberculosis pulmonar extensamente drogorresistente Hospital Sergio Bernales 2013-2016
Marisol Mercedes Ccalli Gutierrez (2018)
10.1111/joim.12264
Totally drug‐resistant tuberculosis and adjunct therapies
S. Parida (2015)
[Evaluation of blood agar medium for the growth of mycobacteria].
A. Çoban (2011)
10.9734/IJTDH/2014/6726
Comparison of Rifampicin Resistance in Mycobacterium tuberculosisIsolatesby Multiplex Allele Specific PCR (MAS-PCR) with Enzyme Linked Immuno sorbent Assay (PCR -ELISA )
A. Velayati (2014)
10.1155/2011/585919
HIV-Associated Tuberculosis
K. Naidoo (2011)
Evaluation of SO-DMT Assay in Sputum Specimens from Hawassa Town , Ethiopia By Abiy Aklilu
Abiy Aklilu (2015)
10.5588/ijtld.11.0116
Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa.
F. Mukinda (2012)
10.1128/AAC.01775-16
eis Promoter C14G and C15G Mutations Do Not Confer Kanamycin Resistance in Mycobacterium tuberculosis
S. Pholwat (2016)
Bottlenecks and recommendations for the incorporation of new technologies in the tuberculosis laboratory network in Brazil.
M. A. Telles (2012)
Novel mutation detection IN rpoB OF rifampicin-resistant Mycobacterium tuberculosis using pyrosequencing.
Pyar Kyi Htike Min (2014)
10.1586/17476348.2.5.583
Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy
D. I. Ling (2008)
Métodos diagnósticos moleculares en tuberculosis Molecular methods in the diagnosis of tuberculosis / Métodos diagnósticos moleculares em tuberculoses
D. Cristina (2013)
See more
Semantic Scholar Logo Some data provided by SemanticScholar